Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trialMace L Rothenberg, P Y Liu, Patricia S Braly, et al.
Gynecologic Oncology|February 22, 2005
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology GroupSidney A Scudder, P Y Liu, Sharon P Wilczynski, et al.
Gynecologic Oncology|July 21, 2004
Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group studyPatrick J Stiff, Elizabeth J Shpall, P Y Liu, et al.
Gynecologic Oncology|May 26, 2009
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancerHarriet O Smith, James Moon, Sharon P Wilczynski, et al.
Anticancer Research|May 16, 2009
Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trialSolomon Jo, Agnes Juhasz, Keqiang Zhang, et al.
Plos One|May 25, 2012
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosisXiwei Wu, Lihong Weng, Xuejun Li, et al.
NPJ Breast Cancer|July 20, 2017
Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630Ronald K Potkul, Joseph M Unger, Robert B Livingston, et al.
Oncogene|August 8, 2002
Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancerEri S Srivatsan, Rita Chakrabarti, Kayvan Zainabadi, et al.
The Journal of Biological Chemistry|October 8, 2020
Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancerMysore S Veena, Santanu Raychaudhuri, Saroj K Basak, et al.
Cancer Research Communications|February 29, 2024
Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of SnailMysore S Veena, Jungmo J Gahng, Mustafa Alani, et al.
Pageof 3